Display options
Cite
Bektur E, Sahin E, Baycu C. Mirtazapine may show anti-hyperglycemic effect by decreasing GLUT2 through leptin and galanin expressions in the liver of type 1 diabetic rats. Iran J Basic Med Sci. 2019;22(6):676-682doi: 10.22038/ijbms.2019.34529.8190.
Bektur, E., Sahin, E., & Baycu, C. (2019). Mirtazapine may show anti-hyperglycemic effect by decreasing GLUT2 through leptin and galanin expressions in the liver of type 1 diabetic rats. Iranian journal of basic medical sciences, 22(6), 676-682. https://doi.org/10.22038/ijbms.2019.34529.8190
Bektur, Ezgi, et al. "Mirtazapine may show anti-hyperglycemic effect by decreasing GLUT2 through leptin and galanin expressions in the liver of type 1 diabetic rats." Iranian journal of basic medical sciences vol. 22,6 (2019): 676-682. doi: https://doi.org/10.22038/ijbms.2019.34529.8190
Bektur E, Sahin E, Baycu C. Mirtazapine may show anti-hyperglycemic effect by decreasing GLUT2 through leptin and galanin expressions in the liver of type 1 diabetic rats. Iran J Basic Med Sci. 2019 Jun;22(6):676-682. doi: 10.22038/ijbms.2019.34529.8190. PMID: 31231496; PMCID: PMC6570756.
Copy Download .nbib Format: NLM
Share it on

Iran J Basic Med Sci. 2019 Jun;22(6):676-682. doi: 10.22038/ijbms.2019.34529.8190.

Mirtazapine may show anti-hyperglycemic effect by decreasing GLUT2 through leptin and galanin expressions in the liver of type 1 diabetic rats.

Iranian journal of basic medical sciences

Ezgi Bektur, Erhan Sahin, Cengiz Baycu

Affiliations

  1. Eskisehir Osmangazi University, Faculty of Medicine, Department of Histology and Embryology, Eskisehir, Turkey.
  2. Okan University, Faculty of Medicine, Department of Histology and Embryology, Istanbul, Turkey.

PMID: 31231496 PMCID: PMC6570756 DOI: 10.22038/ijbms.2019.34529.8190

Abstract

OBJECTIVES: The aim of this study was to explore the molecular mechanism of mirtazapine with respect to energy metabolism in Streptozotocin-induced diabetic liver of rats by immunohistochemistry and Western blot.

MATERIALS AND METHODS: Twenty-one male Sprague-Dawley rats were assigned into 3 groups including control, type 1 diabetes mellitus (T1DM) group (55 mg/kg Streptozocin, IP) and T1DM+mirtazapine (20 mg/kg,PO) group. At the end of the experiment, blood glucose levels were measured and liver tissues were stained by Periodic acid-Schiff. Moreover, leptin and glucose transporter 2 (GLUT2) proteins were analyzed by western blot and immunohistochemistry; however, galanin were analyzed only by immunohistochemistry.

RESULTS: At the end of the study, in diabetes group, blood glucose level, GLUT2 and galanin expressions increased, while leptin expression decreased when compared to control group. Mirtazapine treatment restored the decreased leptin expression, and the increased blood glucose level and galanine expression to the level of the control group. It also decreased the GLUT2 expression even below the control group.

CONCLUSION: We concluded that mirtazapine may show its anti-hyperglycemic effect by decreasing GLUT2 through altering the leptin and galanin expression in the liver of type 1 diabetic rats. Mirtazapine can be used as an antidepressant for T1DM patients and as a drug to reduce blood glucose level in T1DM.

Keywords: GLUT2; Galanin; Leptin; Liver; Mirtazapine; Type 1 diabetes mellitus

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Int J Obes Relat Metab Disord. 1999 Nov;23(11):1207-12 - PubMed
  2. Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2355-60 - PubMed
  3. J Biol Chem. 2000 Apr 14;275(15):11348-54 - PubMed
  4. Mol Endocrinol. 2002 Jul;16(7):1612-28 - PubMed
  5. Regul Pept. 2003 Mar 28;111(1-3):83-90 - PubMed
  6. Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R206-16 - PubMed
  7. FASEB J. 2005 Jun;19(8):1048-50 - PubMed
  8. Neuromolecular Med. 2005;7(1-2):157-80 - PubMed
  9. Neuropsychopharmacology. 2006 Apr;31(4):832-44 - PubMed
  10. Eur Neuropsychopharmacol. 2007 Jan;17(1):64-9 - PubMed
  11. J Clin Psychiatry. 2006 Mar;67(3):421-4 - PubMed
  12. Neuropsychopharmacology. 2008 Oct;33(11):2573-85 - PubMed
  13. Cell Mol Life Sci. 2008 Jun;65(12):1854-63 - PubMed
  14. Cell Mol Life Sci. 2008 Jun;65(12):1796-805 - PubMed
  15. Peptides. 2009 Oct;30(10):1957-63 - PubMed
  16. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):4813-9 - PubMed
  17. IUBMB Life. 2010 May;62(5):315-33 - PubMed
  18. Neuropeptides. 2011 Feb;45(1):1-8 - PubMed
  19. Endocrinology. 2011 Feb;152(2):394-404 - PubMed
  20. Basic Clin Pharmacol Toxicol. 2011 Jun;108(6):365-70 - PubMed
  21. Diabetes. 2011 May;60(5):1414-23 - PubMed
  22. Neurosci Bull. 2011 Dec;27(6):407-12 - PubMed
  23. Fitoterapia. 2012 Jun;83(4):650-9 - PubMed
  24. J Mol Endocrinol. 2012 May 29;49(1):R9-17 - PubMed
  25. Peptides. 2012 Aug;36(2):331-9 - PubMed
  26. Gen Comp Endocrinol. 2012 Oct 1;179(1):115-20 - PubMed
  27. Biochimie. 2013 Feb;95(2):366-73 - PubMed
  28. J Clin Psychopharmacol. 2013 Feb;33(1):99-103 - PubMed
  29. Stem Cells Dev. 2013 Jun 1;22(11):1693-708 - PubMed
  30. Peptides. 2013 Jun;44:55-9 - PubMed
  31. Front Neurosci. 2013 Apr 08;7:51 - PubMed
  32. Br J Pharmacol. 2013 Jul;169(6):1352-71 - PubMed
  33. Gynecol Endocrinol. 2014 Mar;30(3):236-40 - PubMed
  34. Peptides. 2014 Apr;54:186-9 - PubMed
  35. Alzheimers Dement. 2014 Feb;10(1 Suppl):S26-32 - PubMed
  36. Pharmacol Biochem Behav. 2014 May;120:82-7 - PubMed
  37. Psychiatry Investig. 2014 Apr;11(2):167-72 - PubMed
  38. Diabetes. 2014 Jul;63(7):2262-72 - PubMed
  39. Biomed Res Int. 2014;2014:801269 - PubMed
  40. Mech Ageing Dev. 2015 Sep;150:20-6 - PubMed
  41. Chem Biol Interact. 2016 Aug 25;256:161-6 - PubMed
  42. J Agric Food Chem. 2017 Aug 30;65(34):7433-7439 - PubMed
  43. FEBS Lett. 1983 Nov 28;164(1):124-8 - PubMed
  44. Hepatology. 1999 Jan;29(1):166-72 - PubMed

Publication Types